The AI-driven platform provides insights into drug candidates, enabling drug therapists to identify new drugs with maximum efficacy and safety in a shorter time compared to traditional approaches. The platform integrates polypharmacology, selectivity profiling, safety assessments, and drug repurposing into a coherent framework applicable to all stages of drug discovery and development. IBIS' technology predicts how drugs behave in the human body and expected toxicities, and how they perform across both human and viral proteins to select candidates for antiviral testing.